Accuracy of blood-based neurofilament light to different genetic frontotemporal dementia from primary psychiatric disorders
Journal of Alzheimer’s Disease · 2025
DOI: 10.1177/13872877251352103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2025. Verfasst von Ella Liu und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy and Cell Biology, McGill University, Montréal, Québec, Canada. Hauptthemen laut MEDLINE: Frontotemporal Dementia, Neurofilament Proteins, Mental Disorders. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Wellcome Trust.
Themen: Demenz
Abstract (Originalsprache)
Background
Genetic frontotemporal dementia (FTD) along with Alzheimer's disease (AD), is one of the most prevalent early-onset dementias. The differential diagnosis of FTD from primary psychiatric disorder (PPD) has been challenging due to significant symptom overlap, particular as FTD often presents with prolonged psychiatric prodromes.
Objective
This study aims to evaluate whether blood-based neurofilament light chain (NfL) can differentiate genetic FTD from PPD, and to determine a global clinical cutoff to differentiate genetic FTD carriers from PPD with high specificity and sensitivity.
Methods
Data (ages 40–81) were obtained from FTD mutation carriers (GENFI; n = 474; n = 120 C9orf72, n = 114 GRN, n = 50 MAPT , n = 190 controls), and PPD (Biobanque Signature; n = 848). Blood-based NfL was measured with SIMOA HD-X (BbS) and SIMOA HD-1 (GENFI).
Results
Blood-based NfL was higher in all symptomatic mutations compared to PPD. Mildly symptomatic (0 < FTLD CDR-SOB-NM < 4) C9orf72 and GRN carriers also had higher NfL. ROC curve revealed an optimal blood-based NfL cutoff of 22.1 pg/mL ( J = 0.647) to distinguish symptomatic genetic FTD from PPD (78.5% sensitivity, 86.2% specificity, AUC = 0.908). For mildly symptomatic subjects, a cutoff of 16.2 pg/mL ( J = 0.601) differentiated groups with 86.7% sensitivity and 73.5% specificity (AUC = 0.870).
Conclusions
NfL holds potential as a blood-based biomarker for symptomatic genetic FTD carriers, with moderate accuracy to distinguish PPD from mild forms including C9orf72 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomy and Cell Biology, McGill University, Montréal, Québec, Canada.
- Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Verdun, Québec, Canada.
- Amsterdam Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam Neuroscience, Neurodegeneration, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, North Holland, Netherlands.
- Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, Greater London, UK.
- Department of Neurology, Erasmus Medical Centre, Rotterdam, South Holland, Netherlands.
- Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Institut d'Investigacións Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Catalonia, Spain.
ORCID-Profile: Ella Liu, Sherri Lee Jones, Victoria Light, Charlotte Teunissen, Arabella Bouzigues, Lucy L Russell, Phoebe H Foster, Eve Ferry-Bolder, Harro Seelaar, Robert Laforce, Caroline Graff, Daniela Galimberti, Rik Vandenberghe, Alexandre de Mendonça, Isabel Santana, Alexander Gerhard, Johannes Levin, Isabelle Le Ber, Maria Carmela Tartaglia, Matthis Synofzik, Fermin Moreno, Barbara Borroni, Henrik Zetterberg, Simon Ducharme
Förderung
- Wellcome Trust
Zitieren
APA
Liu, E., Jones, S. L., Light, V., Teunissen, C., Bouzigues, A., Russell, L. L., Foster, P. H., Ferry-Bolder, E., van Swieten, J. C., Jiskoot, L. C., Seelaar, H., Sanchez-Valle, R., Laforce, R., Graff, C., Galimberti, D., Vandenberghe, R., de Mendonça, A., Tiraboschi, P., Santana, I., …, & Genetic Frontotemporal Dementia Initiative (GENFI) and Banque Signature (BbS) (2025). Accuracy of blood-based neurofilament light to different genetic frontotemporal dementia from primary psychiatric disorders. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877251352103
Vancouver
Liu E, Jones SL, Light V, Teunissen C, Bouzigues A, Russell LL, et al. Accuracy of blood-based neurofilament light to different genetic frontotemporal dementia from primary psychiatric disorders. Journal of Alzheimer’s Disease. 2025. doi:10.1177/13872877251352103
BibTeX
@article{Liu2025,
author = {Liu, Ella and Jones, Sherri Lee and Light, Victoria and Teunissen, Charlotte and Bouzigues, Arabella and Russell, Lucy L and Foster, Phoebe H and Ferry-Bolder, Eve and van Swieten, John C and Jiskoot, Lize C and Seelaar, Harro and Sanchez-Valle, Raquel and Laforce, Robert and Graff, Caroline and Galimberti, Daniela and Vandenberghe, Rik and de Mendonça, Alexandre and Tiraboschi, Pietro and Santana, Isabel and Gerhard, Alexander and Levin, Johannes and Sorbi, Sandro and Otto, Markus and Butler, Chris R and Ber, Isabelle Le and Finger, Elizabeth and Tartaglia, Maria Carmela and Masellis, Mario and Rowe, James B and Synofzik, Matthis and Moreno, Fermin and Borroni, Barbara and Zetterberg, Henrik and Rohrer, Jonathan D and Ducharme, Simon and Genetic Frontotemporal Dementia Initiative (GENFI) and Banque Signature (BbS), Genetic Frontotemporal Dementia Initiative (GENFI) and Banque Signature (BbS)},
title = {Accuracy of blood-based neurofilament light to different genetic frontotemporal dementia from primary psychiatric disorders},
journal = {Journal of Alzheimer’s Disease},
year = {2025},
doi = {10.1177/13872877251352103}
}
EUVIMED